DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 145 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $12,538,383 | +19.2% | 797,100 | +22.2% | 0.01% | 0.0% |
Q4 2023 | $10,520,857 | +133.5% | 652,254 | +84.2% | 0.01% | +150.0% |
Q3 2023 | $4,505,297 | +29.1% | 354,190 | +42.9% | 0.00% | 0.0% |
Q2 2023 | $3,490,953 | +295743.5% | 247,937 | +224.7% | 0.00% | +100.0% |
Q1 2023 | $1,180 | -86.2% | 76,365 | -85.3% | 0.00% | -75.0% |
Q4 2022 | $8,541 | -100.0% | 521,166 | -47.1% | 0.00% | -60.0% |
Q3 2022 | $18,241,000 | +119.2% | 986,019 | +55.8% | 0.01% | +100.0% |
Q2 2022 | $8,323,000 | +55.8% | 632,936 | +9.8% | 0.01% | +66.7% |
Q1 2022 | $5,342,000 | -34.9% | 576,298 | -31.4% | 0.00% | -25.0% |
Q4 2021 | $8,204,000 | -34.6% | 839,759 | +127.3% | 0.00% | -50.0% |
Q3 2021 | $12,553,000 | +49.2% | 369,411 | +60.8% | 0.01% | +60.0% |
Q2 2021 | $8,411,000 | +110.6% | 229,765 | +158.0% | 0.01% | +66.7% |
Q1 2021 | $3,993,000 | -72.5% | 89,057 | -65.1% | 0.00% | -72.7% |
Q4 2020 | $14,544,000 | +210.8% | 254,847 | +179.4% | 0.01% | +83.3% |
Q3 2020 | $4,679,000 | +311.2% | 91,217 | +378.5% | 0.01% | +200.0% |
Q2 2020 | $1,138,000 | -83.6% | 19,065 | -88.7% | 0.00% | -87.5% |
Q1 2020 | $6,925,000 | +98.0% | 168,186 | +199.3% | 0.02% | +300.0% |
Q4 2019 | $3,498,000 | -96.2% | 56,194 | -97.9% | 0.00% | -97.2% |
Q3 2019 | $91,559,000 | +144.1% | 2,697,699 | +62.2% | 0.14% | +154.4% |
Q2 2019 | $37,509,000 | +28.6% | 1,663,357 | +32.4% | 0.06% | +29.5% |
Q1 2019 | $29,163,000 | +11.4% | 1,256,489 | +0.8% | 0.04% | +7.3% |
Q4 2018 | $26,167,000 | +715.9% | 1,246,640 | +1405.1% | 0.04% | +925.0% |
Q3 2018 | $3,207,000 | +197.8% | 82,825 | +202.7% | 0.00% | +300.0% |
Q2 2018 | $1,077,000 | -77.7% | 27,361 | -88.6% | 0.00% | -83.3% |
Q1 2018 | $4,831,000 | -70.8% | 241,061 | -66.9% | 0.01% | -73.9% |
Q4 2017 | $16,517,000 | +26.4% | 728,583 | +5.9% | 0.02% | +15.0% |
Q3 2017 | $13,070,000 | – | 688,231 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 338,718 | $13,945,020 | 15.33% |
Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |